HALPRYZA®: Rituximab Injection
Products
Information
Received NMPA marketing approval on September, 2020
Approved for Diffuse large b cell lymphoma、Follicular lymphoma、Chronic lymphocytic leukemia
HALPRYZA® has been approved in China for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, all of which are included in the NRDL.